Efficacy and Tolerance of EGb 761 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-Blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70.
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2019
At a glance
- Drugs EGb 761 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Therapeutic Use
- Acronyms GuidAge
- 22 Jun 2010 Primary endpoint 'Disease occurrence' has not been met, according to an Ipsen media release of top-line results.
- 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Apr 2009 Planned end date changed from 1 Jan 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov record (NCT00276510).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History